Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting roughly 1 in 10 women of childbearing age. It can lead to various health issues, including insulin resistance, pre-diabetes, type 2 diabetes, and obesity. Living with PCOS is a constant struggle; it's not just about managing symptoms, but also battling misconceptions about the condition. It's an actual medical condition, not a result of lifestyle choices or poor dieting habits.

Tirzepatide, a cutting-edge GLP-1 receptor agonist, is already FDA-approved to treat type 2 diabetes. This medication has shown great promise in improving insulin sensitivity and contributing to weight loss, which are crucial aspects of managing PCOS. Many women with PCOS have experienced remarkable success when using Tirzepatide off-label, a testament to its potential in enhancing their quality of life.

Despite its promising benefits, Tirzepatide is not yet FDA-approved for treating PCOS, leaving many women to pay out of pocket for this potentially life-changing medication. This creates a significant financial barrier and reduces access to effective management of their condition.

We urge the FDA to consider the benefits and success stories surrounding Tirzepatide for PCOS treatment. Approving it for this purpose would help mitigate long-term health risks associated with PCOS, improve lives, and ensure that more women gain access through insurance coverage.

Join us in advocating for a change that could benefit millions of women battling PCOS. Sign this petition to push for FDA approval of Tirzepatide as a viable treatment option for PCOS.